Literature DB >> 29289455

Arterial thrombosis and anti-PD-1 blockade.

Céline Boutros1, Jean-Yves Scoazec2, Christine Mateus3, Emilie Routier3, Séverine Roy3, Caroline Robert4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29289455     DOI： 10.1016/j.ejca.2017.11.018

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  10 in total

1.  Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.

Authors:  Florian Moik; Wei-Shin Evelyn Chan; Sarah Wiedemann; Christoph Hoeller; Felix Tuchmann; Marie-Bernadette Aretin; Thorsten Fuereder; Sabine Zöchbauer-Müller; Matthias Preusser; Ingrid Pabinger; Cihan Ay
Journal:  Blood       Date:  2021-03-25       Impact factor: 22.113

Review 2.  Old is new again: emergence of thromboembolic complications in cancer patients on immunotherapy.

Authors:  Keith R McCrae; Shadi Swaidani; C Marcela Diaz-Montero; Alok A Khorana
Journal:  Thromb Res       Date:  2022-05-26       Impact factor: 10.407

3.  Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients.

Authors:  Federico Nichetti; Francesca Ligorio; Emma Zattarin; Diego Signorelli; Arsela Prelaj; Claudia Proto; Giulia Galli; Antonio Marra; Giulia Apollonio; Luca Porcu; Filippo de Braud; Giuseppe Lo Russo; Roberto Ferrara; Marina Chiara Garassino
Journal:  Cancers (Basel)       Date:  2019-12-25       Impact factor: 6.639

Review 4.  In situ Pulmonary Artery Thrombosis: A Previously Overlooked Disease.

Authors:  Yunshan Cao; Chao Geng; Yahong Li; Yan Zhang
Journal:  Front Pharmacol       Date:  2021-07-08       Impact factor: 5.810

5.  Immunotherapy-induced acute pulmonary thromboembolism: A case report.

Authors:  Waseem Abbas; Gaurav Dixit; Ranga Raju Rao; Vineet Govinda Gupta; Swati Popli
Journal:  South Asian J Cancer       Date:  2019 Jul-Sep

6.  Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.

Authors:  Tamara A Sussman; Hong Li; Brian Hobbs; Pauline Funchain; Keith R McCrae; Alok A Khorana
Journal:  J Immunother Cancer       Date:  2021-01       Impact factor: 12.469

7.  Immune checkpoint inhibitors-associated thrombosis in patients with lung cancer and melanoma: a study of the Spanish society of medical oncology (SEOM) thrombosis and cancer group.

Authors:  Manuel Sánchez Cánovas; David Fernández Garay; Laura Ortega Moran; Jaime Rubio Pérez; Carlos Miguel Guirao Rubio; Miriam Lobo de Mena; Berta Obispo Portero; Jesús Brenes Castro; Yolanda Lage; Diego Cacho Lavin; Ana Belen Rupérez Blanco; Ana Manuela Martín Fernández de Soignie; Jonatan Zacarías Benoit Perejón; Laura Jiménez Colomo; Noel Blaya Boluda; Javier Bosque Moreno; Teresa Quintanar Verduguez; Carmen Rosa Garrido; Roberto Martín Huertas; Carme Font I Puig; Andrés Jesús Muñoz Martín
Journal:  Clin Transl Oncol       Date:  2022-06-06       Impact factor: 3.340

8.  Immune checkpoint inhibitors and potential risk of thromboembolic events: Analysis of the WHO global database of individual case safety reports.

Authors:  Eman A Alghamdi; Hadir Aljohani; Waad Alghamdi; Fawaz Alharbi
Journal:  Saudi Pharm J       Date:  2022-06-21       Impact factor: 4.562

9.  Thromboembolic Events Related to Treatment with Checkpoint Inhibitors: Report of Two Cases.

Authors:  Jessica Tsukamoto; Mariana Monteiro; Silvana Vale; Cynthia Lemos; Thais Scarpelli; Leticia Carvalho; Daniela Pezzutti; Raphael Brandão
Journal:  Case Rep Oncol       Date:  2018-10-22

Review 10.  Vascular toxic effects of cancer therapies.

Authors:  Joerg Herrmann
Journal:  Nat Rev Cardiol       Date:  2020-03-26       Impact factor: 32.419
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.